2024-11-13 | [Corrections] Correction to Lancet HIV 2024; 11: e783–90 | | |
2024-11-11 | [Series] Interventions to ensure access to and continuity of HIV care for international migrants: an evidence synthesis | Alena Kamenshchikova, Charlotte M M Peters, Christiana Nöstlinger, Brian Rice, Nathan Ford, Giovanni Ravasi, Fiona Burns, Milosz Parczewski, Christian J P A Hoebe, Nicole Dukers, Farah Seedat, Antons Mozalevskis, Linda-Gail Bekker, Jean Berchmans Tugirima | |
2024-11-11 | [Series] Humanising and optimising HIV health care for refugees and asylum seekers | Claudia P Cortes, Omar Sued, William C W Wong, Annick Borquez, Charles Ssonko, Miłosz Parczewski, Jocelyn DeJong, Vonthanak Saphonn, Animesh Sinha, Báltica Cabieses | |
2024-11-11 | [Comment] Addressing HIV prevention and the PrEP gap among migrants | Christiana Nöstlinger | |
2024-11-11 | [Comment] Ensuring the right to health for migrants and refugees | Andrea L Wirtz, Kathleen R Page, Paul B Spiegel | |
2024-11-08 | [Comment] Outcomes and gaps in HIV care for migrants in Europe | Deniz Gökengin | |
2024-11-08 | [Articles] HIV-related outcomes among migrants living in Europe compared with the general population: a systematic review and meta-analysis | Francesco Vladimiro Segala, Francesco Di Gennaro, Luisa Frallonardo, Elda De Vita, Valentina Petralia, Vitalba Sapienza, Stefano Di Gregorio, Mariangela Cormio, Roberta Novara, Giuseppina Rizzo, Mario Barbagallo, Nicola Veronese, Annalisa Saracino | |
2024-11-07 | [Corrections] Correction to Lancet HIV 2024; 11: e736–45 | | |
2024-11-07 | [Feature] Highlights of the 5th HIVR4P Conference | Adrian Gonzalez-Lopez | |
2024-10-30 | [Correspondence] Screening for chlamydia and incidence of symptomatic infections | Thibaut Vanbaelen, Achilleas Tsoumanis, Chris Kenyon | |
2024-10-30 | [Correspondence] Antiretrovirals and obesity | Nikos Pantazis, Kholoud Porter, Caroline A Sabin, Fiona Burns, Giota Touloumi | |
2024-10-26 | [Review] Sex as a biological variable in HIV-1 and schistosome co-infection | Jane K Maganga, Khanh Pham, John M Changalucha, Jennifer A Downs | |
2024-10-19 | [Comment] Injectable treatment for adolescents living with HIV | Phakamani Moyo, Damaris Nyamweya, Nyiko Kubai, Catherine Orrell, Linda-Gail Bekker | |
2024-10-12 | [Articles] Safety and efficacy of iron supplementation with 3 months of daily ferrous sulphate in children living with HIV and mild-to-moderate anaemia in Uganda: a double-blind, randomised, placebo-controlled trial | Anne E P Frosch, Victor Musiime, Christopher Staley, Andrea L Conroy, Diana Rutebarika, Gilbert Ategeka, Sarah E Cusick | |
2024-10-12 | [Comment] Iron supplementation among children living with HIV | Ajibola I Abioye, Wafaie W Fawzi | |
2024-10-10 | [Articles] Dynamic choice HIV prevention with cabotegravir long-acting injectable in rural Uganda and Kenya: a randomised trial extension | Moses R Kamya, Laura B Balzer, James Ayieko, Jane Kabami, Elijah Kakande, Gabriel Chamie, Nicole Sutter, Helen Sunday, Janice Litunya, Joshua Schwab, John Schrom, Melanie Bacon, Catherine A Koss, Alex R Rinehart, Maya Petersen, Diane V Havlir, SEARCH Cons | |
2024-10-10 | [Comment] Another step forward in implementing long-acting PrEP | Quanhathai Kaewpoowat, Michael E Ohl | |
2024-10-09 | [Articles] Extreme weather events and disruptions to HIV services: a systematic review | Collins C Iwuji, Celia McMichael, Euphemia Sibanda, Kingsley S Orievulu, Kelly Austin, Kristie L Ebi | |
2024-10-09 | [Comment] Measuring and adapting to climate change in HIV programmes | Nathan Ford, Anne Hammill | |
2024-09-28 | [Articles] HIV incidence in people receiving government-subsidised pre-exposure prophylaxis in Australia: a whole-of-population retrospective cohort study | Nicholas A Medland, Hamish McManus, Benjamin R Bavinton, Doug Fraser, Michael W Traeger, Andrew E Grulich, Mark A Stoove, Skye McGregor, Jonathan M King, Dash Heath-Paynter, Rebecca J Guy | |
2024-09-26 | [Profile] Supporting Poland's LGBT+ community through thick and thin | Ed Holt | |
2024-09-25 | [Review] Role of HIV self-testing in strengthening HIV prevention services | Ying Zhang, Cheryl C Johnson, Van Thi Thuy Nguyen, Jason J Ong | |
2024-09-25 | [Culture] A career dedicated to public service | Talha Burki | |
2024-09-21 | [Articles] Health impact, budget impact, and price threshold for cost-effectiveness of lenacapavir for HIV pre-exposure prophylaxis in eastern and southern Africa: a modelling analysis | Linxuan Wu, David Kaftan, Rachel Wittenauer, Cory Arrouzet, Nishali Patel, Arden L Saravis, Brian Pfau, Edinah Mudimu, Anna Bershteyn, Monisha Sharma | |
2024-09-21 | [Comment] Cost-effectiveness of lenacapavir for PrEP in Africa | Dvora Joseph Davey, Lise Jamieson | |
2024-09-14 | [Articles] Cognitive performance, neuropsychiatric symptoms, and cerebrospinal fluid viral control following programmatic switch from efavirenz-based to dolutegravir-based antiretroviral therapy in South Africa (CONNECT): a prospective cohort study | Sam Nightingale, Anna J Dreyer, Kevin G F Thomas, Gert van Zyl, Eric Decloedt, Petrus J W Naude, Catherine Orrell, Phumla Sinxadi, Alan Winston, Saye Khoo, John A Joska | |
2024-09-14 | [Comment] Antiretroviral efficacy versus neurotoxicity | Graciela Cárdenas | |
2024-09-12 | [Corrections] Correction to Lancet HIV 2024; 11: e233–44 | | |
2024-09-06 | [Articles] Optimising HIV spending in 12 eastern European and central Asian countries: a modelling study | Debra C ten Brink, Anna L Bowring, Rowan Martin-Hughes, Nisaa Wulan, Yinzong Xiao, Kelvin Burke, Tom Tidhar, Tom Walsh, Sherrie L Kelly, Andrew Shattock, Tom Palmer, Corina Maxim, Shufang Zhang, Nick Scott | |
2024-09-06 | [Comment] Optimising HIV spending in eastern Europe and central Asia | Gesine Meyer-Rath, Jeffrey W Imai-Eaton | |
2024-09-05 | [Articles] Bacterial sexually transmitted infections among men who have sex with men and transgender women using oral pre-exposure prophylaxis in Latin America (ImPrEP): a secondary analysis of a prospective, open-label, multicentre study | Mayara Secco Torres Silva, Thiago Silva Torres, Carolina Coutinho, Ronaldo Ismério Moreira, Iuri da Costa Leite, Marcelo Cunha, Pedro Henrique Amparo da Costa Leite, Carlos F Cáceres, Hamid Vega-Ramírez, Kelika A Konda, Juan Guanira, José Valdez Madruga, | |
2024-09-05 | [Comment] Preventing sexually transmitted infections in the age of PrEP | Javier R Lama, Ann Duerr | |
2024-08-30 | [Corrections] Correction to Lancet HIV 2024; published online Aug 16. https://doi.org/10.1016/S2352-3018(24)00173-5 | | |
2024-08-24 | [Articles] Changes in bodyweight after initiating antiretroviral therapy close to HIV-1 seroconversion: an international cohort collaboration | Nikos Pantazis, Caroline A Sabin, Sophie Grabar, Marc Van der Valk, Inma Jarrin, Ard van Sighem, Laurence Meyer, Christina Carlander, John Gill, Alain Volny Anne, Bruno Spire, Shema Tariq, Fiona Burns, Dominique Costagliola, Elisa Ruiz-Burga, Giota Toulou | |
2024-08-24 | [Comment] Untangling the causal ties between antiretrovirals and obesity | Jennifer Manne-Goehler, Mark J Siedner | |
2024-08-22 | [Comment] Complex response to HIV and tuberculosis in South Sudan | Antonio Flores, Buai Tut Chol, Jane Alphonse, Tess Hewett | |
2024-08-21 | [Culture] All roads lead to Westminster: the infected blood scandal | Catherine Lucas | |
2024-08-17 | [Viewpoint] The long wait for long-acting HIV prevention and treatment formulations | Willem Daniel Francois Venter, Monica Gandhi, Simiso Sokhela, Kenly Sikwese, Helen Bygrave, Louis Da Gama, Ndiviwe Mphothulo, Lise Jamieson, Mark J Siedner, Anton L Pozniak, Pablo Rojo, Solange L Baptiste, Jacque Wambui, Gesine Meyer-Rath, Brian Honermann | |
2024-08-03 | [Articles] Identifying risk factors for anal cancer in people with HIV in Spain: a multicentre retrospective cohort study nested in the PISCIS cohort | Josep M Llibre, Boris Revollo, Jordi Aceiton, Yesika Díaz, Pere Domingo, Joaquim Burgos, Patricia Sorni, Maria Saumoy, Hernando Knobel, Marta Navarro, Elena Leon, Amat Orti, Laia Arbonés, Arantxa Mera, Elisabet Deig, Guillem Sirera, Josep M Miró, Jordi Ca | |
2024-08-03 | [Comment] Optimising anal cancer screening through risk stratification | Elena Sendagorta, Pedro Herranz | |
2024-08-02 | [Articles] Impact of financial incentives on viral suppression among adults initiating HIV treatment in Tanzania: a hybrid effectiveness–implementation trial | Prosper F Njau, Emmanuel Katabaro, Solis Winters, Amon Sabasaba, Kassim Hassan, Babuu Joseph, Hamza Maila, Janeth Msasa, Carolyn A Fahey, Laura Packel, William H Dow, Nicholas P Jewell, Nzovu Ulenga, Natalino Mwenda, Sandra I McCoy | |
2024-08-02 | [Comment] Incentivising engagement in care among people with HIV | P J Smith, H Thirumurthy | |
2024-07-24 | [Position Paper] Analytical treatment interruption in children living with HIV: position statement from the EPIICAL consortium | Louise Kuhn, Shaun Barnabas, Nicola Cotugno, Holly Peay, Philip Goulder, Mark Cotton, Avy Violari, Savita Pahwa, Kavidha Reddy, Alfredo Tagarro, Kennedy Otwombe, Samantha Fry, Paula Vaz, Maria Grazia Lain, Tacilta Nhampossa, Moherndran Archary, Almoustaph | |
2024-07-23 | [Articles] The contribution of intimate partner violence to vertical HIV transmission: a modelling analysis of 46 African countries | Salome Kuchukhidze, Magdalene K Walters, Dimitra Panagiotoglou, Marie-Claude Boily, Souleymane Diabaté, W Alton Russell, Heidi Stöckl, Lynnmarie Sardinha, Francisco Mbofana, Rhoda K Wanyenze, Jeffrey W Imai-Eaton, Mathieu Maheu-Giroux | |
2024-07-23 | [Comment] Addressing partner violence to end infant HIV infection | A M Hatcher, L Kimbo | |
2024-07-21 | [The Lancet HIV Commissions] IAPAC–Lancet HIV Commission on the future of urban HIV responses | José M Zuniga, Corey Prachniak, Nicoletta Policek, Nombulelo Magula, Anisha Gandhi, Jane Anderson, Dázon Dixon Diallo, Viviane Dias Lima, Sindhu Ravishankar, Shrikala Acharya, Angeli Achrekar, Monsurat Adeleke, Élodie Aïna, Solange Baptiste, Geoffrey Barr | |
2024-07-20 | [Culture] Creativity until you drop dead | Talha Burki | |
2024-07-13 | [Articles] HIV-1 infection kinetics, drug resistance, and long-term safety of pre-exposure prophylaxis with emtricitabine plus tenofovir alafenamide (DISCOVER): week 144 open-label extension of a randomised, controlled, phase 3 trial | David A Wohl, Christoph D Spinner, Jason Flamm, C Bradley Hare, Susanne Doblecki-Lewis, Peter J Ruane, Jean-Michel Molina, Anthony Mills, Cynthia Brinson, Moti Ramgopal, Amanda Clarke, Gordon Crofoot, Claudia Martorell, Christoph Carter, Stephanie Cox, J | |
2024-07-13 | [Correspondence] Madagascar urgently needs a 2024 national prevalence survey of HIV | Audrey Geoffroy, Luc Samison, Fidiniaina Randriatsarafara, Haja Randriantsara, ZA Randriamanantany, Christophe Vanhecke | |
2024-07-13 | [Comment] Novel anti-obesity drugs for people with HIV | Nomathemba Chandiwana, Jennifer Manne-Goehler, Lobna Gaayeb, Alexandra Calmy, Willem D F Venter | |
2024-07-13 | [Comment] Reassuring long-term safety, resistance, and efficacy data for two daily formulations of PrEP | Deborah Donnell | |
2024-07-10 | [Position Paper] Person-centred care for older adults living with HIV in sub-Saharan Africa | Deborah Goldstein, Jepchirchir Kiplagat, Charlotte Taderera, Erin R Whitehouse, Cleophas Chimbetete, Sylvester Kimaiyo, Sarah Urasa, Stella-Maria Paddick, Catherine Godfrey | |
2024-07-09 | [Articles] Potential population-level effects of HIV self-test distribution among key populations in Côte d'Ivoire, Mali, and Senegal: a mathematical modelling analysis | Romain Silhol, Mathieu Maheu-Giroux, Nirali Soni, Arlette Simo Fotso, Nicolas Rouveau, Anthony Vautier, Clémence Doumenc-Aïdara, Olivier Geoffroy, Kouassi Noel N'Guessan, Younoussa Sidibé, Odé Kanku Kabemba, Papa Alioune Gueye, Pauline Dama Ndeye, Christi | |
2024-07-09 | [Comment] Effects of self-testing on HIV outcomes in west Africa | Karin Hatzold, Yasmin Dunkley | |
2024-07-06 | [Articles] Impact of a point-of-care urine tenofovir assay on adherence to HIV pre-exposure prophylaxis among women in Kenya: a randomised pilot trial | Monica Gandhi, David V Glidden, Deepalika Chakravarty, Guohong Wang, Charlene Biwott, Peter Mogere, Gakuo Maina, Irene Njeru, Catherine Kiptinness, Phelix Okello, Matthew A Spinelli, Purba Chatterjee, Jennifer Velloza, Vallery Ogello, Andrew Medina-Marino | |
2024-07-06 | [Comment] Low-cost point-of-care urine test to enhance PrEP adherence | Iuri da Costa Leite, Daniel Savignon Marinho | |
2024-07-05 | [Viewpoint] Steatotic liver disease and HIV: an agenda for 2030 | Juan M Pericàs, Anish K Arora, Carlotta Riebensahm, Alba Jiménez-Masip, Adrià Ramírez Mena, Trenton M White, Nikos Dedes, Giovanni Guaraldi, Annalisa Berzigotti, Gilles Wandeler, Meena B Bansal, Jordi Navarro, Jeffrey V Lazarus | |
2024-06-29 | [Profile] Mandala: helping combat HIV in Georgia | Ed Holt | |
2024-06-29 | [Feature] Legislation threat to services for LGBTQ+ people in Georgia | Ed Holt | |
2024-06-18 | [Culture] Recent gay Black history in the UK | Talha Burki | |
2024-06-14 | [Editorial] Long-overdue conclusion to the UK Infected Blood Inquiry | The Lancet HIV | |
2024-06-08 | [Feature] UK Infected Blood Inquiry highlights decades of failings | Talha Burki | |
2024-06-07 | [Personal View] Moving beyond hotspots of HIV prevalence to geospatial hotspots of UNAIDS 95-95-95 targets in sub-Saharan Africa | Diego F Cuadros, Qian Huang, Godfrey Musuka, Tafadzwa Dzinamarira, Brian K Moyo, Amon Mpofu, Tatenda Makoni, F DeWolfe Miller, Anna Bershteyn | |
2024-06-05 | [Articles] Longitudinal evolution of the HIV effective reproduction number following sequential expansion of treatment as prevention and pre-exposure prophylaxis in British Columbia, Canada: a population-level programme evaluation | Viviane D Lima, Jielin Zhu, Rolando Barrios, Junine Toy, Jeffrey B Joy, Brian G Williams, Reuben Granich, Zunyou Wu, Jason Wong, Julio S G Montaner | |
2024-06-05 | [Comment] Reducing HIV transmission in British Columbia, Canada | Ann Duerr, Chris Beyrer | |
2024-06-01 | [Corrections] Correction to Lancet HIV 2024; 11: e285–99 | | |
2024-05-31 | [Articles] Transition times across the HIV care continuum in Spain from 2005 to 2022: a longitudinal cohort study | Alejandro G García-Ruiz de Morales, María Jesús Vivancos, María de Lagarde, Margarita Ramírez Schacke, Maria del Mar Arcos Rueda, Eva Orviz, Adrian Curran, Francisco Carmona-Torre, Santiago Moreno, María Jesús Pérez-Elías, Javier Martínez-Sanz, Cohort of | |
2024-05-31 | [Comment] Reducing time to viral suppression in Europe | Lise Cuzin, Pascal Pugliese | |
2024-05-22 | [Articles] Dolutegravir plus boosted darunavir versus recommended standard-of-care antiretroviral regimens in people with HIV-1 for whom recommended first-line non-nucleoside reverse transcriptase inhibitor therapy has failed (D2EFT): an open-label, rando | D2EFT Study Group | |
2024-05-22 | [Comment] Second-line HIV treatments for adults in LMICs | Esaú C João | |
2024-05-11 | [Comment] Closing the equity gap in the treatment of HIV-2 infection | Sarah Rowland-Jones, Ester Gea-Mallorquí | |
2024-05-11 | [Articles] Efficacy and safety of three antiretroviral therapy regimens for treatment-naive African adults living with HIV-2 (FIT-2): a pilot, phase 2, non-comparative, open-label, randomised controlled trial | Serge P Eholie, Didier K Ekouevi, Corine Chazallon, Charlotte Charpentier, Eugène Messou, Zelica Diallo, Jacques Zoungrana, Albert Minga, Ndeye Fatou Ngom Gueye, Denise Hawerlander, Fassery Dembele, Géraldine Colin, Boris Tchounga, Sophie Karcher, Jérome | |
2024-05-09 | [Articles] Switch to fixed-dose doravirine (100 mg) with islatravir (0·75 mg) once daily in virologically suppressed adults with HIV-1 on antiretroviral therapy: 48-week results of a phase 3, randomised, open-label, non-inferiority trial | Jean-Michel Molina, Giuliano Rizzardini, Catherine Orrell, Alejandro Afani, Alexandra Calmy, Shinichi Oka, Federico Hinestrosa, Princy Kumar, Pablo Tebas, Sharon Walmsley, Anjana Grandhi, Stephanie Klopfer, Isaias Gendrano, Karen Eves, Todd A Correll, Mic | |
2024-05-09 | [Comment] Is this the end of the road for daily islatravir 0·75 mg? | Jennifer Hoy, James McMahon | |
2024-05-09 | [Articles] Switch to fixed-dose doravirine (100 mg) with islatravir (0·75 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of a phase 3, randomised, controlled, double-b | Anthony M Mills, Giuliano Rizzardini, Moti N Ramgopal, Olayemi O Osiyemi, Johannes R Bogner, Debbie P Hagins, Roger Paredes, Jacques Reynes, Jürgen K Rockstroh, Andrew Carr, Feng-Hsiu Su, Stephanie O Klopfer, Karen Eves, Rebeca M Plank, Todd Correll, Mich | |
2024-05-01 | [Correspondence] Context-specific estimates of vertical transmission | Souleymane Tassembedo, Isidore Tiandiogo Traore, Abdoul-Salam Ouedraogo, Nicolas Meda, Philippe Van de Perre, Nicolas Nagot, Fati Kirakoya-Samadoulougou | |
2024-04-30 | [Viewpoint] Two-drug regimens for the treatment of HIV in Africa | Ivan Mambule, Claire Norcross, Loice Achieng Ombajo, Simiso Sokhela, Eva Agnes Laker Odongpiny, Noela Owarwo, David S Lawrence, Eugene Ruzagira, Fiona V Cresswell | |
2024-04-13 | [Articles] Pharmacokinetics and safety of coformulated bictegravir, emtricitabine, and tenofovir alafenamide in children aged 2 years and older with virologically suppressed HIV: a phase 2/3, open-label, single-arm study | Carina A Rodriguez, Eva Natukunda, Renate Strehlau, Esme L Venter, Supattra Rungmaitree, Coleen K Cunningham, Umesh Lalloo, Pope Kosalaraksa, Elizabeth HellstrÖm, Afaaf Liberty, Eric J McGrath, Meenu Kaur, Rory Leisegang, Jason T Hindman, Vinicius A Vieir | |
2024-04-13 | [Articles] Associations between change in BMI and the risk of hypertension and dyslipidaemia in people receiving integrase strand-transfer inhibitors, tenofovir alafenamide, or both compared with other contemporary antiretroviral regimens: a multicentre, | Dathan M Byonanebye, Mark N Polizzotto, Fernando Maltez, Andri Rauch, Katharina Grabmeier-Pfistershammer, Ferdinand Wit, Stéphane De Wit, Antonella Castagna, Antonella d'Arminio Monforte, Cristina Mussini, Jan-Christian Wasmuth, Eric Fontas, Irene Abela, | |
2024-04-13 | [Comment] Expanding options of child-friendly, single-tablet regimens for young children with HIV | Tim R Cressey, Anna Turkova | |
2024-04-13 | [Comment] More pressure on integrase strand-transfer inhibitors? | Anton L Pozniak, W D Francois Venter | |
2024-04-09 | [Review] Non-suppressible viraemia during HIV-1 therapy: a challenge for clinicians | Andrés Esteban-Cantos, Rocío Montejano, Adriana Pinto-Martínez, Javier Rodríguez-Centeno, Federico Pulido, José R Arribas | |
2024-04-06 | [Corrections] Correction to Lancet HIV 2024; 11: e86–95 | | |
2024-04-05 | [Articles] Voucher incentives to improve viral suppression among HIV-positive people who inject drugs and men who have sex with men in India: a cluster randomised trial | Sunil S Solomon, Allison M McFall, Aylur K Srikrishnan, Vinita Verma, Santhanam Anand, Rifa T Khan, Bhawani Singh Kushwaha, Canjeevaram Vasudevan, Shanmugam Saravanan, Nandagopal Paneerselvam, Muniratnam Suresh Kumar, Chinmoyee Das, David D Celentano, Shr | |
2024-04-05 | [Comment] Enhancing HIV care with incentives: one size does not fit all | Sandra I McCoy, Amon Sabasaba | |
2024-04-04 | [Comment] Intersectional climate justice, health equity, and HIV | Sarah M Wilson, Griffin Woolley, Chris Hawn, Kate Hoffman, Akhenaton-Andrew D Jones, Cliburn Chan, Sarah V Mudrak, M Umar Qureshi, Ashley Ward, Elizabeth T Knippler, N Lance Okeke, Amy Corneli, Georgia D Tomaras, R Keith Reeves | |
2024-03-29 | [Corrections] Correction to Lancet HIV 2024; 11: e64–65 | | |
2024-03-28 | [Feature] Tajikistan's tentative steps to tackling HIV | Ed Holt | |
匿名用户只展示最新 100 条榜单历史,更多历史数据请登录后查看,支持时光机按天筛选